Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4047127 | 0.86 | GABRA1 (0.42) | CCR1GABRA1GABRG2GABRB3TRPV3 | |
| SCHEMBL20416692 | 0.84 | CCR1 (0.39) | CCR1GABRA1GABRG2GABRB3TRPV3 | |
| SCHEMBL29337105 | 0.82 | IRAK4 (0.44) | CCR1IRAK4 | |
| SCHEMBL20738460 | 0.82 | CCR1 (0.42) | CCR1GABRA1GABRG2GABRB3TRPV3 | |
| SCHEMBL20400486 | 0.82 | CCR1 (0.38) | CCR1GABRA1GABRG2GABRB3TRPV3 | |
| SCHEMBL2936127 | 0.82 | IRAK4 (0.44) | CCR1IRAK4 | |
| SCHEMBL20436438 | 0.81 | TSHR (0.37) | CCR1GABRA1GABRG2GABRB3IRAK4 | |
| SCHEMBL23006785 | 0.80 | IRAK4 (0.38) | IRAK4CXCR4 | |
| SCHEMBL17349929 | 0.79 | CCR1 (0.35) | CCR1GABRA1GABRG2GABRB3TRPV3 | |
| SCHEMBL20416689 | 0.79 | CCR1 (0.35) | CCR1GABRA1GABRG2GABRB3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | CCR1 1669/4885GABRA1 99/4885GABRG2 95/4885 |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | BRS3, BDKRB2, NTSR2 | CCR1 1669/4885GABRA1 99/4885GABRG2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.